Target intelligence / Profile preview

DNA polymerase lambda (Pol λ)

Target
Pol λ
Molecular classification
Enzyme, DNA polymerase (X family), DNA repair enzyme
01

Overview

DNA polymerase lambda is a eukaryotic DNA repair enzyme, encoded by the POLL gene in humans, and a member of the X family of DNA polymerases[1][3]. It is primarily involved in DNA double-strand break repair by non-homologous end joining and in base excision repair, functioning mainly to fill short gaps during these processes[1][3][5]. Structurally, it possesses a catalytic polymerase domain, an 8 kDa lyase domain (removing 5′-deoxyribose phosphate), and a BRCT domain for protein interactions, enabling it to stabilize DNA ends and bridge gaps[1][3]. DNA polymerase lambda is also implicated in certain translesion DNA synthesis events and contributes to immune system diversity via V(D)J recombination. Its fidelity differs from replicative polymerases, with an error profile marked by relatively high rates of single-nucleotide deletions[3]. While no approved therapeutics directly target Pol λ, its central role in repair pathways positions it as a potential research target in oncology and immunology[1][3][5].

Other names
POLLDNA polymerase lambda (human gene symbol: POLL)Pol lambda
02

Mechanism of action

Not applicable; no specific drugs target Pol λ directly. Its inhibition or modulation would, in principle, impair DNA double-strand break repair via NHEJ/BER and potentially sensitize cells to DNA damage.

03

Biological functions

DNA repair (particularly non-homologous end joining, NHEJ)Base excision repair (BER)Gap-filling DNA synthesisV(D)J recombination (immune receptor gene assembly)Translesion synthesis (DNA damage tolerance)
04

Disease associations

Cancer (pol λ activity and fidelity may contribute to genome stability and cancer susceptibility)Immunodeficiency (role in immune receptor diversity through V(D)J recombination)
05

Safety considerations

Potential for genomic instability or increased mutagenesis if function is dysregulated or inhibited[3].Targeting may affect immune cell development due to its role in V(D)J recombination[1].
06

Interacting drugs

None reported as approved or clinically relevant modulators specifically targeting DNA polymerase lambda; no small molecule inhibitors in routine clinical use known at this time[1][3][5].
07

Biomarkers

No established clinical biomarkers for patient selection; research may use POLL gene expression as a proxy for DNA repair capacity in cancer[1].

Beyond the preview

Go deeper on DNA polymerase lambda (Pol λ).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on DNA polymerase lambda (Pol λ).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call